Market Research Logo

Thrombocytopenia - Pipeline Review, H1 2015

Thrombocytopenia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Thrombocytopenia - Pipeline Review, H1 2015’, provides an overview of the Thrombocytopenia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Thrombocytopenia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Thrombocytopenia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Thrombocytopenia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Thrombocytopenia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Thrombocytopenia Overview
Therapeutics Development
Pipeline Products for Thrombocytopenia - Overview
Pipeline Products for Thrombocytopenia - Comparative Analysis
Thrombocytopenia - Therapeutics under Development by Companies
Thrombocytopenia - Therapeutics under Investigation by Universities/Institutes
Thrombocytopenia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Thrombocytopenia - Products under Development by Companies
Thrombocytopenia - Products under Investigation by Universities/Institutes
Thrombocytopenia - Companies Involved in Therapeutics Development
Ablynx NV
Anthera Pharmaceuticals‚ Inc.
Archemix Corp.
Arcturus Therapeutics, Inc
aTyr Pharma, Inc.
Bayer AG
BioLineRx, Ltd.
Boehringer Ingelheim GmbH
Bolder Biotechnology, Inc.
Bristol-Myers Squibb Company
Cellerant Therapeutics, Inc.
Eisai Co., Ltd.
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
HanAll Biopharma Co., Ltd.
Immunomedics, Inc.
InvivoGen Therapeutics
Jiangsu Hengrui Medicine Co., Ltd.
Kaketsuken K.K.
Merck & Co., Inc.
Momenta Pharmaceuticals, Inc.
Myelo Therapeutics GmbH
Neumedicines Inc.
Novartis AG
Octapharma AG
Omeros Corporation
Pfizer Inc.
PhytoHealth Corporation
Portola Pharmaceuticals, Inc.
Prophylix Pharma AS
Protalex, Inc.
Rigel Pharmaceuticals, Inc.
Shionogi & Co., Ltd.
STATegics, Inc.
ViroMed Co., Ltd.
Thrombocytopenia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Antibody for Autoimmune Disorders and Inflammation - Drug Profile
ARC-15105 - Drug Profile
avatrombopag - Drug Profile
BAX-930 - Drug Profile
BBT-030 - Drug Profile
BBT-045 - Drug Profile
BI-655064 - Drug Profile
BL-8040 - Drug Profile
blisibimod - Drug Profile
BMS-986004 - Drug Profile
caplacizumab - Drug Profile
CLT-009 - Drug Profile
eltrombopag olamine - Drug Profile
fostamatinib disodium - Drug Profile
GBR-600 - Drug Profile
Gene Therapy for Chemotherapy-Induced Thrombocytopenia - Drug Profile
GL-2045 - Drug Profile
GSK-2285921 - Drug Profile
Hetrombopag Olamine - Drug Profile
HL-161 - Drug Profile
LUNAR-TPO - Drug Profile
lusutrombopag - Drug Profile
MK-8723 - Drug Profile
Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile
Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile
Myelo-001 - Drug Profile
NMIL-121 - Drug Profile
Oligonucleotides to Activate miRNA-150 for Thrombocytopenia - Drug Profile
OMS-721 - Drug Profile
PEG-VM501 - Drug Profile
PHN-013 - Drug Profile
plasma (human) - Drug Profile
PRT-060318 - Drug Profile
PRTX-100 - Drug Profile
rivaroxaban - Drug Profile
SM-101 - Drug Profile
STST-4 - Drug Profile
Tmax - Drug Profile
Tromplate - Drug Profile
TXA-302 - Drug Profile
veltuzumab - Drug Profile
Thrombocytopenia - Recent Pipeline Updates
Thrombocytopenia - Dormant Projects
Thrombocytopenia - Discontinued Products
Thrombocytopenia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Thrombocytopenia, H1 2015
Number of Products under Development for Thrombocytopenia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Thrombocytopenia - Pipeline by Ablynx NV, H1 2015
Thrombocytopenia - Pipeline by Anthera Pharmaceuticals‚ Inc., H1 2015
Thrombocytopenia - Pipeline by Archemix Corp., H1 2015
Thrombocytopenia - Pipeline by Arcturus Therapeutics, Inc, H1 2015
Thrombocytopenia - Pipeline by aTyr Pharma, Inc., H1 2015
Thrombocytopenia - Pipeline by Bayer AG, H1 2015
Thrombocytopenia - Pipeline by BioLineRx, Ltd., H1 2015
Thrombocytopenia - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Thrombocytopenia - Pipeline by Bolder Biotechnology, Inc., H1 2015
Thrombocytopenia - Pipeline by Bristol-Myers Squibb Company, H1 2015
Thrombocytopenia - Pipeline by Cellerant Therapeutics, Inc., H1 2015
Thrombocytopenia - Pipeline by Eisai Co., Ltd., H1 2015
Thrombocytopenia - Pipeline by GlaxoSmithKline Plc, H1 2015
Thrombocytopenia - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015
Thrombocytopenia - Pipeline by HanAll Biopharma Co., Ltd., H1 2015
Thrombocytopenia - Pipeline by Immunomedics, Inc., H1 2015
Thrombocytopenia - Pipeline by InvivoGen Therapeutics, H1 2015
Thrombocytopenia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015
Thrombocytopenia - Pipeline by Kaketsuken K.K., H1 2015
Thrombocytopenia - Pipeline by Merck & Co., Inc., H1 2015
Thrombocytopenia - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015
Thrombocytopenia - Pipeline by Myelo Therapeutics GmbH, H1 2015
Thrombocytopenia - Pipeline by Neumedicines Inc., H1 2015
Thrombocytopenia - Pipeline by Novartis AG, H1 2015
Thrombocytopenia - Pipeline by Octapharma AG, H1 2015
Thrombocytopenia - Pipeline by Omeros Corporation, H1 2015
Thrombocytopenia - Pipeline by Pfizer Inc., H1 2015
Thrombocytopenia - Pipeline by PhytoHealth Corporation, H1 2015
Thrombocytopenia - Pipeline by Portola Pharmaceuticals, Inc., H1 2015
Thrombocytopenia - Pipeline by Prophylix Pharma AS, H1 2015
Thrombocytopenia - Pipeline by Protalex, Inc., H1 2015
Thrombocytopenia - Pipeline by Rigel Pharmaceuticals, Inc., H1 2015
Thrombocytopenia - Pipeline by Shionogi & Co., Ltd., H1 2015
Thrombocytopenia - Pipeline by STATegics, Inc., H1 2015
Thrombocytopenia - Pipeline by ViroMed Co., Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Thrombocytopenia Therapeutics - Recent Pipeline Updates, H1 2015
Thrombocytopenia - Dormant Projects, H1 2015
Thrombocytopenia - Dormant Projects (Contd..1), H1 2015
Thrombocytopenia - Dormant Projects (Contd..2), H1 2015
Thrombocytopenia - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Thrombocytopenia, H1 2015
Number of Products under Development for Thrombocytopenia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report